Aripiprazole lauroxil

Public-database records for Aripiprazole lauroxil (CAS 1259305-29-7), reproduced here for independent cross-checking.

Safety classification and hazard statements

Physical description and handling notes

• Aripiprazole, which is a major pharmacological metabolite of aripiprazole lauroxil, serves to improve the positive and negative symptoms of schizophrenia by modulating dopaminergic signalling pathways. Aripiprazole lauroxil is reported to have minimal effects on sexual function or prolactin levels.

Reported physical properties

How this substance is indexed

Documented uses

• Aripiprazole lauroxil is indicated for the treatment of schizophrenia and related psychotic disorders.
• SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
• Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
• Following a single extended-release intramuscular injection of aripiprazole lauroxil, aripiprazole can be detected in the systemic circulation from 5 to 6 days and is continued to be released for an additional 36 days. The concentrations of aripiprazole increases with consecutive doses of aripiprazole lauroxil and the steady state is reached following the fourth monthly injection. The systemic exposure to aripiprazole was similar when comparing deltoid and gluteal intramuscular injections.
• Based on the pharmacokinetic study for aripiprazole, less than 1% of unchanged aripiprazole was excreted in the urine and approximately 18% of the oral dose was recovered unchanged in the feces.
• Based on population pharmacokinetic analysis, the apparent volume of distribution of aripiprazole following intramuscular injection of aripiprazole lauroxil was 268 L, indicating extensive extravascular distribution following absorption. Health human volunteer study indicates that aripiprazole crosses the blood-brain barrier.

Names this substance appears under

Aripiprazole lauroxil; 1259305-29-7; Aristada; RDC-3317; ALKS 9072; Aristada initio; ALKS 9070; RDC 3317; ALKS-9070; ALKS-9072; RDC3317; B786J7A343; CHEBI:90930; DTXSID60154997; (7-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl dodecanoate; [7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-2-oxo-3,4-dihydroquinolin-1(2H)-yl]methyl dodecanoate

Computed molecular descriptors

Database abstract

Aripiprazole lauroxil · CAS 1259305-29-7 · C36H51Cl2N3O4. UNII B786J7A343. 熔点: 81-83; 溶解度: <0.01 mg/mL; LogP: 5.3.

Source: PubChem / Wikidata; the batch COA governs where values differ.